Author

Arno R. Bourgonje

THE EFFECT OF PHENOTYPE AND GENOTYPE ON THE PLASMA PROTEOME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
THE EFFECT OF PHENOTYPE AND GENOTYPE ON THE PLASMA PROTEOME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IN-DEPTH CHARACTERIZATION OF THE SERUM ANTIBODY EPITOPE REPERTOIRE IN INFLAMMATORY BOWEL DISEASE BY HIGH-THROUGHPUT PHAGE-DISPLAYED IMMUNOPRECIPITATION SEQUENCING
IN-DEPTH CHARACTERIZATION OF THE SERUM ANTIBODY EPITOPE REPERTOIRE IN INFLAMMATORY BOWEL DISEASE BY HIGH-THROUGHPUT PHAGE-DISPLAYED IMMUNOPRECIPITATION SEQUENCING

Arno R. Bourgonje  et al.

TYPE I COLLAGEN DEGRADATION FRAGMENTS (C1M) AND HUMAN NEUTROPHIL ELASTASE-DERIVED FRAGMENTS OF CALPROTECTIN (CPA9-HNE) REFLECT BIOCHEMICAL AND ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
TYPE I COLLAGEN DEGRADATION FRAGMENTS (C1M) AND HUMAN NEUTROPHIL ELASTASE-DERIVED FRAGMENTS OF CALPROTECTIN (CPA9-HNE) REFLECT BIOCHEMICAL AND ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Arno R. Bourgonje  et al.

SYSTEMIC IRON DEFICIENCY AND INTESTINAL INFLAMMATION CONTROL GUT MUCOSAL HIF-1? AND TFRC ACTIVATION IN INFLAMMATORY BOWEL DISEASE
SYSTEMIC IRON DEFICIENCY AND INTESTINAL INFLAMMATION CONTROL GUT MUCOSAL HIF-1? AND TFRC ACTIVATION IN INFLAMMATORY BOWEL DISEASE

DISTINCT MUCOSAL HOST-MICROBE INTERACTIONS IN RELATION TO CLINICAL PHENOTYPES IN INFLAMMATORY BOWEL DISEASE
DISTINCT MUCOSAL HOST-MICROBE INTERACTIONS IN RELATION TO CLINICAL PHENOTYPES IN INFLAMMATORY BOWEL DISEASE

Arno R. Bourgonje  et al.

SEROLOGICAL BIOMARKERS OF TYPE I, III, AND IV COLLAGEN TURNOVER ARE ASSOCIATED WITH THE PRESENCE AND FUTURE PROGRESSION OF STRICTURING AND PENETRATING CROHN'S DISEASE
SEROLOGICAL BIOMARKERS OF TYPE I, III, AND IV COLLAGEN TURNOVER ARE ASSOCIATED WITH THE PRESENCE AND FUTURE PROGRESSION OF STRICTURING AND PENETRATING CROHN'S DISEASE

Arno R. Bourgonje  et al.

TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE
TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE

Arno R. Bourgonje  et al.

SYSTEMIC IRON DEFICIENCY AND INTESTINAL INFLAMMATION CONTROL GUT MUCOSAL HIF-1? AND TFRC ACTIVATION IN INFLAMMATORY BOWEL DISEASE
SYSTEMIC IRON DEFICIENCY AND INTESTINAL INFLAMMATION CONTROL GUT MUCOSAL HIF-1? AND TFRC ACTIVATION IN INFLAMMATORY BOWEL DISEASE

Arno R. Bourgonje  et al.

PROTEOMIC ANALYSES DO NOT REVEAL SUBCLINICAL INFLAMMATION IN FATIGUED PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE
PROTEOMIC ANALYSES DO NOT REVEAL SUBCLINICAL INFLAMMATION IN FATIGUED PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE

Arno R. Bourgonje  et al.

TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS
TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS
TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

Arno R. Bourgonje  et al.

TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE
TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE

THE EFFECT OF PHENOTYPE AND GENOTYPE ON THE PLASMA PROTEOME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
THE EFFECT OF PHENOTYPE AND GENOTYPE ON THE PLASMA PROTEOME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Arno R. Bourgonje  et al.

PROTEOMIC ANALYSES DO NOT REVEAL SUBCLINICAL INFLAMMATION IN FATIGUED PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE
PROTEOMIC ANALYSES DO NOT REVEAL SUBCLINICAL INFLAMMATION IN FATIGUED PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE

DISTINCT MUCOSAL HOST-MICROBE INTERACTIONS IN RELATION TO CLINICAL PHENOTYPES IN INFLAMMATORY BOWEL DISEASE
DISTINCT MUCOSAL HOST-MICROBE INTERACTIONS IN RELATION TO CLINICAL PHENOTYPES IN INFLAMMATORY BOWEL DISEASE

SEROLOGICAL BIOMARKERS OF TYPE I, III, AND IV COLLAGEN TURNOVER ARE ASSOCIATED WITH THE PRESENCE AND FUTURE PROGRESSION OF STRICTURING AND PENETRATING CROHN'S DISEASE
SEROLOGICAL BIOMARKERS OF TYPE I, III, AND IV COLLAGEN TURNOVER ARE ASSOCIATED WITH THE PRESENCE AND FUTURE PROGRESSION OF STRICTURING AND PENETRATING CROHN'S DISEASE

TYPE I COLLAGEN DEGRADATION FRAGMENTS (C1M) AND HUMAN NEUTROPHIL ELASTASE-DERIVED FRAGMENTS OF CALPROTECTIN (CPA9-HNE) REFLECT BIOCHEMICAL AND ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
TYPE I COLLAGEN DEGRADATION FRAGMENTS (C1M) AND HUMAN NEUTROPHIL ELASTASE-DERIVED FRAGMENTS OF CALPROTECTIN (CPA9-HNE) REFLECT BIOCHEMICAL AND ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

IN-DEPTH CHARACTERIZATION OF THE SERUM ANTIBODY EPITOPE REPERTOIRE IN INFLAMMATORY BOWEL DISEASE BY HIGH-THROUGHPUT PHAGE-DISPLAYED IMMUNOPRECIPITATION SEQUENCING
IN-DEPTH CHARACTERIZATION OF THE SERUM ANTIBODY EPITOPE REPERTOIRE IN INFLAMMATORY BOWEL DISEASE BY HIGH-THROUGHPUT PHAGE-DISPLAYED IMMUNOPRECIPITATION SEQUENCING

USE OF TUMOR NECROSIS FACTOR-ALPHA ANTAGONISTS IS ASSOCIATED WITH ATTENUATED IGG ANTIBODY RESPONSE AGAINST SARS-COV-2 IN VACCINATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
USE OF TUMOR NECROSIS FACTOR-ALPHA ANTAGONISTS IS ASSOCIATED WITH ATTENUATED IGG ANTIBODY RESPONSE AGAINST SARS-COV-2 IN VACCINATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Arno R. Bourgonje  et al.

BIOMARKERS OF EXTRACELLULAR MATRIX TURNOVER AND NEUTROPHIL ACTIVITY PREDICT LONG-TERM RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE
BIOMARKERS OF EXTRACELLULAR MATRIX TURNOVER AND NEUTROPHIL ACTIVITY PREDICT LONG-TERM RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE

Arno R. Bourgonje  et al.

Item 1 - 20 / 28
1
2